IPO - Profile

Connect Biopharma Holdings Ltd.

Health Care > Major Pharmaceuticals



We are a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets. Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis, or AD, and asthma. More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 11,250,000 Positive High 28.39%

Offering Team

  • Legal counsel
  • Davis Polk & Wardwell LLP
  • Auditors
  • PricewaterhouseCoopers Zhang Tian LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 18 Mar, 2021

Offer 19 Mar, 2021

Look Ahead

Lock Up Expiry Sep 19, 2021

IPO Terms

Offer Price $17.00
Offer Size 11M

Market Sentiments

Stock Price